✨
AI Summary
- Gilead Sciences allegedly delayed a promising HIV treatment for profit.
- The company prioritized existing patents over releasing a better drug.
- This case reveals perverse incentives within the pharmaceutical industry.
Guests on This Episode
RR
Rebecca Robbins
3 podcast appearances